All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.

  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub
Brought to you by Scientific Education Support

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more
Symposium | The role of nurses within the multidisciplinary GvHD care team
Symposium | The role of nurses within the multidisciplinary GvHD care team
Michelle Kenyon, King’s College Hospital NHS Foundation Trust, London, UK presented the first session, titled “The role of nurses within the multidisciplinary GvHD care team” at the recent GvHD Hub live symposium.
May 6, 2026|EBMT 2026
FDA approves once-daily, extended-release tablet formulation of ruxolitinib for GvHD
FDA approves once-daily, extended-release tablet formulation of ruxolitinib for GvHD
On May 1, 2026, the FDA approved a once-daily, extended-release tablet formulation of ruxolitinib for patients aged ≥12 years ...
May 5, 2026|Ruxolitinib
Umbilical cord-derived MSCs for SR-aGvHD: A real-world study
Umbilical cord-derived MSCs for SR-aGvHD: A real-world study
Results from a single-center real-world study, evaluating umbilical cord-derived MSCs plus 2L SoC in patients with SR-aGvHD, were published in Leukemi...
May 5, 2026|Mesenchymal stromal cells
EBMT‑PDWP registry study: Impact of aGvHD on allo-HSCT outcomes in pediatric ALL
EBMT‑PDWP registry study: Impact of aGvHD on allo-HSCT outcomes in pediatric ALL
Results from a retrospective European Society for Blood and Marrow Transplantation (EBMT)-Pediatric Diseases Working Party (PDWP) ...
May 1, 2026|Pediatric GvHD
Carousel item
Carousel item
Carousel item
Mohamad Mohty
Mohamad Mohty

"The new GvHD Hub is an amazing resource for physicians and healthcare professionals in the field of GvHD. We have recently seen some great advances in this era, and the GvHD Hub is the place to go for the most up-to-date information."

Your opinion matters

What do you consider to be the main potential advantage of mesenchymal stromal cells in the treatment of acute GvHD?

Recent content

VIEW ALL
European real-world use of belumosudil for the treatment of cGvHD
European real-world use of belumosudil for the treatment of cGvHD
Here, we present a summary of real-world data from three European multicenter retrospective analyses of belumosudil for the treatment of chronic ...
Apr 30, 2026|cGvHD
Efficacy and safety of belumosudil for heavily pretreated cGvHD: Update from the German-Austrian MAP
Efficacy and safety of belumosudil for heavily pretreated cGvHD: Update from the German-Austrian MAP
During the 52nd Annual Meeting of the EBMT, Udo Holtick presented updated findings from a retrospective, multi...
Apr 30, 2026|EBMT 2026
ECP-based combinations for steroid-refractory/dependent acute and chronic GvHD
ECP-based combinations for steroid-refractory/dependent acute and chronic GvHD
During the 52nd Annual Meeting of the EBMT, Simon Bulley presented results from an analysis of pharmacy and medical records, evaluat...
Apr 28, 2026|EBMT 2026
ABC phase I/IIb interim analysis: PTCy dose reduction in calcineurin- and mTOR inhibitor-free GvHD prophylaxis
ABC phase I/IIb interim analysis: PTCy dose reduction in calcineurin- and mTOR inhibitor-free GvHD prophylaxis
During the 52nd Annual Meeting of the EBMT, A Samer Al‑Homsi presented interim results from the phas...
Apr 23, 2026|EBMT 2026

Most read

Response dynamics to belumosudil: ROCKstar ad hoc analysis
Response dynamics to belumosudil: ROCKstar ad hoc analysis
We summarize findings from an ad hoc analysis of the ROCKstar trial, presented by Zachariah DeFilipp et al. at the 67th ASH Annual Meeting and Expositio...
Mar 31, 2026|cGvHD
Acute and chronic GvHD: An overview
Acute and chronic GvHD: An overview
An overview of acute and chronic GvHD, including its etiology, types, symptoms, diagnosis, and management strategies.
Sep 24, 2024
NCCN guidelines for allo-HSCT and management of GvHD: Version 3.2025
NCCN guidelines for allo-HSCT and management of GvHD: Version 3.2025
The National Comprehensive Cancer Network (NCCN) guidelines for hematopoietic stem cell transplantation (HSCT), with a focus on the diagnosis ...
Oct 27, 2025|GvHD
EBMT 2026 | Top abstracts: What’s hot in GvHD?
EBMT 2026 | Top abstracts: What’s hot in GvHD?
To help navigate the exciting content being presented at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub S...
Mar 18, 2026|EBMT 2026

Steering Committee meetings

VIEW ALL
MSCs: From clinical trials to clinical practice
MSCs: From clinical trials to clinical practice
During the GvHD Hub Steering Committee meeting in December 2025, Robert Zeiser, Mohamad Mohty, Yi-Bin Chen, Daniel Wolff, Florent Malard, Corey Cutler, and Andrew ...
Feb 10, 2026|Mesenchymal stromal cells
How can measurement of QoL and use of PROs be improved in cGvHD?
How can measurement of QoL and use of PROs be improved in cGvHD?
During the GvHD Hub Steering Committee Meeting on May 12, 2025, key opinion leaders met to discuss how to improve measurement of QoL and use of PR...
Jul 3, 2025|SR GvHD
ECP + ruxolitinib to prevent cGvHD in patients with SR-aGvHD
ECP + ruxolitinib to prevent cGvHD in patients with SR-aGvHD
During the GvHD Hub Steering Committee Meeting on May 12, 2025, key opinion leaders met to discuss the use of ECP + ruxolitinib to prevent cGvHD in pa...
Jun 25, 2025|SR GvHD
cGvHD: Answering the unanswered
cGvHD: Answering the unanswered
During the GvHD Hub Steering Committee meeting on November 26, 2024, Steven Pavletic chaired a discussion on answering the unanswered in chronic graft-versus-host disease.
Feb 5, 2025

GvHD Hub symposiums

VIEW ALL
Symposium | The role of nurses within the multidisciplinary GvHD care team
Symposium | The role of nurses within the multidisciplinary GvHD care team
Michelle Kenyon, King’s College Hospital NHS Foundation Trust, London, UK presented the first session, titled “The role of nurses within...
May 6, 2026|EBMT 2026
Symposium Series | Guidance vs practice: How can we improve treatment of SR-GvHD?
Symposium Series | Guidance vs practice: How can we improve treatment of SR-GvHD?
The GvHD Hub held a virtual symposium on October 21, 2025, titled Guidance vs practice: How can we improve treatment of SR-GvHD? ...
Nov 25, 2025|SR GvHD
Symposium | Early treatment strategies for SR-GvHD
Symposium | Early treatment strategies for SR-GvHD
Daniel Wolff, University Hospital Regensburg, DE, presented the first session at the recent GvHD Hub virtual symposium, titled, Early treatment strategies for S...
Nov 24, 2025|SR GvHD
Symposium | Quality of life and symptoms in cGvHD
Symposium | Quality of life and symptoms in cGvHD
Steven Pavletic, Bethesda, US, presented the final session – titled, Quality of life and symptoms in cGvHD – at the recent GvHD Hub virtual symposium.
Nov 21, 2025|SR GvHD

Drug updates

VIEW ALL
Important announcement
🚨NEWS🚨 @US_FDA approves once-daily, extended-release tablet formulation of ruxolitinib for patients aged ≥12 years with steroid-refractory #aGvHD or #cGvHD after 1–2 prior lines of systemic therapy. Read more: https://bit.ly/4dlHDBv
May 5, 2026
Important announcement
@TGAGovAU approves axatilimab, a first-in-class anti-CSF-1R antibody, under priority review in Australia for adult and pediatric patients aged ≥6 years (≥40 kg) with #cGvHD after ≥2 prior systemic therapies; based on phase II AGAVE-201 data. Read more: prn.to/3Pph5WR
May 5, 2026
Important announcement
@US_FDA approves the investigational new drug application for a phase Ib/IIa trial of CK0802, an allogeneic CAR-engineered NK cell therapy, for the treatment of patients with SR-GvHD. Read more: prn.to/3Pk1AiY
May 5, 2026
Important announcement
@US_FDA grants RMAT designation to Orca-Q, an investigational allogeneic T-cell therapy, for the treatment of high-risk hematologic malignancies; based on promising OS, #GvHD, and NRM data from an ongoing phase I trial. Read more: bit.ly/4eQcU0r
Apr 29, 2026